Audio

Jeffrey A. Cohen, MD, Describes His Comparison of Alemtuzumab and Interferon Beta-1a in Patients With Multiple Sclerosis

Neurology Reviews. 2012 June;20(6)

 

To read the accompanying article, please click here.

Recommended Reading

Measles Antibody Levels Increase Over Time in Patients With MS
ICYMI Multiple Sclerosis
New and Noteworthy Information
ICYMI Multiple Sclerosis
Comorbid Migraine and Multiple Sclerosis Can Pose Challenges for Neurologists
ICYMI Multiple Sclerosis
Low Level of Vitamin D Is a Risk Factor for Multiple Sclerosis
ICYMI Multiple Sclerosis
Patients With Multiple Sclerosis Have Altered Metabolic Flexibility
ICYMI Multiple Sclerosis
New and Noteworthy Information—May
ICYMI Multiple Sclerosis
Society of Interventional Radiology, 37th Annual Meeting, San Francisco
ICYMI Multiple Sclerosis
Alemtuzumab Will Help Clinicians Treat Patients With MS More Effectively—By Mark Gudesblatt, MD
ICYMI Multiple Sclerosis
Alemtuzumab May Be Superior to Interferon Beta-1a in Patients With MS—Results From the CARE-MS II Study
ICYMI Multiple Sclerosis
Alemtuzumab May Provide Greater Benefit Than Interferon Beta-1a for Treatment-Naïve Patients With MS—Results From the CARE-MS I Study
ICYMI Multiple Sclerosis